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OVERVIEW 
Amyotrophic lateral sclerosis (ALS) is a multifactorial disease characterized by the 
progressive degeneration of motor neurons (MN) and muscle paralysis. Despite current 
treatments, patients survive less than 3–5 years after the initial diagnosis. Most ALS cases 
are sporadic (sALS), and only 5-10% have a familial origin (fALS). Among the latter, about 
20% express a dominant mutant form of the Cu, Zn superoxide dismutase (SOD1) 
(Rothstein, 2009). Transgenic mice expressing a mutant SOD1 develop MN pathology, with 
muscle denervation and weakness similar to ALS patients (Fischer et al., 2004). Many 
evidence demonstrate that ALS is non-cell autonomous, with multiple co-players involved 
in disease progression (Robberecht et al, 2013). In particular, signals from both glial cells 
and muscles initiate and sustain MN degeneration (Boillée et al., 2006; Dobrowolny et al, 
2008). Recent studies described a critical role for microglia in amyotrophic lateral sclerosis 
(ALS), where these CNS-resident immune cells participate in the establishment of an 
inflammatory microenvironment that contributes to motor neuron degeneration. 
Understanding the mechanisms leading to microglia activation in ALS could help to identify 
specific molecular pathways which could be targeted to reduce or delay motor neuron 
degeneration and muscle paralysis in patients. The intermediate-conductance calcium-
activated potassium channel KCa3.1 has been reported to modulate the “pro-inflammatory” 
phenotype of microglia in different pathological conditions. We here investigated the effects 
of blocking KCa3.1 activity in the hSOD1G93AALS mouse model, which recapitulates many 
features of the human disease. We report that treatment of hSOD1G93A mice with a selective 
KCa3.1 inhibitor, 1-[(2-chlorophenyl) diphenylmethyl]-1H-pyrazole (TRAM-34), attenuates 
the “pro-inflammatory” phenotype of microglia in the spinal cord, reduces motor neuron 
death, delays onset of muscle weakness, and increases survival. Specifically, inhibition of 
KCa3.1 channels slowed muscle denervation, decreased the expression of the fetal 
acetylcholine receptor γ subunit and reduced neuromuscular junction damage. Taken 
together, these results demonstrate a key role for KCa3.1 in driving a pro-inflammatory 
microglia phenotype in ALS.  
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INTRODUCTION 
1. Amyotrophic Lateral Sclerosis (ALS) 
Amyotrophic lateral sclerosis (ALS) is a fatal, adult-onset neurodegenerative disease that is 
characterized by the degeneration of both upper motor neurons (that is, neurons that project 
from the cortex to the brainstem and the spinal cord) and lower motor neurons (that is, 
neurons that project from the brainstem or spinal cord to muscle), leading to paralysis and 
death of the patient in mean 3–5 years after the onset of disease. 
 
1.1 Introduction/Background 
The earliest cases of ALS were probably described by Aran (1848)1 and Cruveilhier (1853)2 
although it was not until 1869 that the specific entity we now recognize as ALS was 
formally defined and identified by Charcot3. Its name reflects both the degeneration of 
corticospinal motor neurons, the descending axons of which in the lateral spinal cord seem 
scarred (lateral sclerosis), and the demise of spinal motor neurons, with secondary 
denervation and muscle wasting (amyotrophy). ALS is known as Lou Gehrig’s disease in 
the United States and as motor neuron disease in the United Kingdom. Traditionally, ALS 
has been classified as either the sporadic or familial form. About 10% of cases are 
considered “familial ALS” (FALS) and five major genes are currently associated with 
familial ALS (C9orf72, SOD1, FUS, TARDBP and TBK1)4,5,6. The SOD1 gene was the first 
associated with ALS and most ALS mouse models currently used are based upon 
overexpression of mutant forms of SOD17. Primary symptoms begin as mild cramps or 
weakness in the limbs or bulbar muscles which then progress to paralysis of almost all 
skeletal muscles. Some subsets of motor neurons, including those that innervate the 
extraocular muscles or sphincters, are spared until late in the progression of the disease. 
Beyond motor symptoms, up to 50% ALS patients develop cognitive and/or behavioral 
impairment during the course of disease, and 13% of patients have cognitive abnormalities 
common to frontotemporal dementia (FTD)8. Protein aggregates of hexanucleotide repeat 
expansion in C9orf72 (encoding guanine nucleotide exchange C9orf72) have been detected 
in both ALS and frontotemporal dementia patients9. 
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1.2 Epidemiology 
Most population-based epidemiological studies of ALS have been combined to form the 
European ALS Epidemiology Consortium (EURALS), which has provided data comparing 
the incidence of ALS between European countries. According to the latest studies, the 
incidence of ALS varies according to ancestral origin; studies in populations of European 
origin have shown a greater incidence (2.6-3.0 cases per 100,000 individuals10) than in East 
Asia (~ 0.8 cases per 100,000 individuals) and in South Asia (~ 0.7 cases per 100,000 
individuals). In some regions (such as Guam and the Kii peninsula in Japan) the reported 
incidence was very high but has decreased substantially in the last 30 years for reasons that 
are not clear. Evidence suggests that the incidence and prevalence of ALS is lower in 
populations of mixed ancestral origin than in European populations, with differences in age 
of onset in genetically heterogeneous populations. In populations of European ancestry, the 
median age of onset of sporadic ALS is 65 years, whereas in genetically heterogeneous 
populations is about 10 years earlier 11. In most population-based studies, ALS is found to be 
more common in men than in women, affecting 1.2–1.5 men for every woman12. In Europe, 
most men have spinal-onset disease, and women have a higher propensity for bulbar-onset 
diseas11. The main limitation of the global epidemiology of ALS is that about 80% of studies 
have been conducted in Europe and the United States. The risk of developing ALS peaks 
peaks between 50–75 years of age and decreases thereafter, compared to Alzheimer’s 
disease. Survival is highly variable, but respiratory failure usually leads to death about 3–4 
years after onset13. In the future, it will be necessary to deepen the researches to understand 
the roles of ancestry, genetics and environmental exposure in the causality of ALS. 
 
1.3 Mechanisms and pathophysiology 
Autopsies of people with ALS reveal the degeneration of motor neurons in the motor cortex 
of the brain, in the brainstem motor nuclei and in the anterior horns of the spinal cord and 
diffuse astrocytic gliosis and microglial infiltration in the gray and white matter of the spinal 
cord. Skeletal muscle shows features of denervation and reinnervation, with fiber type 
grouping and clusters of angular atrophic fibers. Although the fundamental 
pathophysiological mechanisms underlying ALS are not yet well known, the 
neuropathological sign of the disease is the aggregation and accumulation of ubiquitous 
protein inclusions in motor neurons. Other pathological features are associated with specific 
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genes. For example, cases of ALS caused by a large expansion of a hexanucleotide repeat in 
C9orf7214 as well as neuronal cytoplasmic inclusions containing the protein DNA binding 
protein 43 (TDP-43), encoded by the TARDBP gene, which is the main component of 
ubiquitous inclusions in most cases of ALS15. Or again, cases of ALS caused by mutations 
in the SOD1 or FUS genes show abnormal SOD1 or FUS protein inclusions, respectively 
(table 1, from Hardiman et al., Nature Reviews Disease Primers, 2017). In addition to these 
alterations in motor neurons, there is also abundant evidence of relevant pathology in non-
neural cell types (eg, astrogliosis and microgliosis) that could negatively influence disease 
progression. A very important discovery was the identification of dominant mutations in the 
SOD1 gene, which encodes a abundant and ubiquitous cytoplasmic enzyme called Cu-Zn 
superoxide dismutase7,17,18, an important antioxidant.  
 
 
      Hardiman et al., Nature Reviews Disease Primers, 2017 
 
The normal function of SOD1 is to catalyze the conversion of highly reactive superoxide to 
hydrogen peroxide or oxygen. The expression of the mutant SOD1 in mice demonstrated 
that motor neuron degeneration is determined by one or more acquired toxicities of the 
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mutant protein and is independent of the activity of dismutase19,20,21. The gene mutations 
that cause ALS are expressed in many types of cells and this means that the disease is the 
result of a combination of SOD1 mutant damage both in motoneurons and in their glial 
partners, rather than damage to neurons alone. It is now clear that ALS acts through non 
cell-autonomous mechanisms. For example, studies in mice expressing mutated SOD1 
reveal that high levels of expression in all motor neurons are not sufficient to cause early-
onset disease19. In contrast, a reduction in the synthesis of the mutant SOD1 in 
motoneurones does not slow down the rate of progression after the onset of the disease, even 
if applied before the symptoms occur22,23.  
Therefore, ALS is a disease not only of the motor neuron but also of the motor system, 
which is composed of motor neurons and intimately associated cells of different types. Great 
progress has been made with the development of pathology models in rats, mice, zebrafish, 
flies, worms and yeasts to study how mutations cause motor neuron degeneration and to 
modulate the biological processes that are thought to be important in disease pathology. 
Obviously, these models have limitations and none recapitulates completely human disease. 
The main reason is that all these models are based on gene overexpression (with multiple 
copies of the human variant inserted in the transgenic model) and because human 
neurotransmission differs substantially from that of the lower animals. In ALS, different 
pathophysiological mechanisms are implicated in motor neuronal damage, although these 
mechanisms are often interconnected. SOD1 is the longest studied gene implicated in ALS 
and has been linked to the greatest number of pathophysiological mechanisms. Aberrant 
RNA metabolism24,25and altered protein homeostasis26 are predominant factors that link 
multiple causal ALS genes to neuronal damage. Mitochondrial dysfunction can result from a 
mutation in CHCHD10 and secondary respiratory chain deficiencies that result from protein 
aggregates generated in the presence of other ALS-associated mutations27. Both cases lead 
to an increase in oxidative stress, which places additional stress on an already compromised 
protein homeostasis system. Other mechanisms of ALS can directly alter neuronal function 
(such as alteration of nuclear export, altered DNA repair and transport of dysregulated 
vesicle) and dysfunction of glial cells28,29. Furthermore, neuronal hyperexcitability30,31 and 
axon dysfunction have been implicated in ALS32. Each of these factors contributes to the 
general pathology of the human disease, but it would be wrong to think that all these factors 
are involved in all cases of ALS, since the human disease is heterogeneous. Nevertheless, 
they represent our current knowledge base on the pathophysiology of ALS and are the 
starting point for current and future therapeutic initiatives. 
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1.4 Diagnosis, screening and therapies 
Diagnosing ALS is based on the El Escorial and Airlie House criteria33-34. Diagnosis 
according to these criteria is used for patients who have a history of progressive weakness 
spreading within a region or to other regions (bulbar, cervical, thoracic, or lumbar), with 
evidence of the involvement of lower motor neurons (through the presence of specific 
symptoms or evidence of denervation on electromyography) and upper motor neurons 
(clinical). Genetic testing can also be included in patients with a family history of ALS35 and 
clinical evidence of disease, although this is not uniformly applied across centres36. The 
heterogeneous clinical presentation and varying speed of progression make diagnosis of 
ALS challenging.  Several biochemical prognosis markers have been reported, including 
serum urate, serum creatinine, serum chloride and increased serum neurofilament levels and 
in CSF37. The worsening of respiratory function, assessed by measuring slow vital capacity, 
forced vital capacity and nasal inspiratory pressure, is also related to short survival38,39,40. 
MRI studies have reported corticospinal tract degeneration, with extensive involvement of 
the frontal and temporal regions and basal ganglia in patients with ALS, compared with 
controls. Furthermore, these analyses are also supported by studies using spectral 
electroencephalography41 and findings that patients with different degrees of cognitive 
impairment have significantly different patterns of frontal lobe metabolic impairment when 
assessed using 18F–fluorodeoxyglucose PET imaging42. However, these types of tests can 
not provide individualized data that can be used as a reliable biomarker of upper motor 
neuron dysfunction or cognitive impairment in ALS patients. Weight loss is common in 
ALS and is multifactorial (muscle loss, hypermetabolism, difficulty eating [swallowing, 
shortness of breath] or decreased appetite)43. If weight loss is greater than 10% of body 
weight, the guidelines recommend that patients undergo gastrostomy to nurture and support 
feeding and medication44. Furthermore, non-invasive ventilation has been shown to prolong 
survival with a larger effect size than riluzole, but unfortunately it is not always feasible, 
particularly for patients with cognitive or bulbar impairment impairment45. However, the 
results of a large cohort study (n = 929)46 suggest that non-invasive ventilation also 
improves survival in patients with bulbar onset, so all patients should be offered non-
invasive ventilation, even when it is likely that the procedure is poorly tolerated. 
Although over 50 drugs have been studied with different mechanisms of action for the 
treatment of ALS, only two compounds (riluzole and edaravone) have been approved. 
Riluzole was the first FDA-approved treatment for ALS and, the drug works by reducing 
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glutamatergic neurotransmission by blocking voltage-gated sodium channels on presynaptic 
neurons. Published data showed that riluzole increased 3-month survival after 18 months of 
treatment compared to placebo, but had no significant effect on muscle strength47. Riluzole 
is a relatively safe drug, although the most common adverse effects are an increase in liver 
enzymes and asthenia; and some cases of fatal hepatic failure and pancreatic arthritis have 
been reported48. Edaravone, which is believed to act as an antioxidant, may slow the 
progression of the disease in patients with early onset and rapidly progressing disease49; and 
it has been approved by the FDA but not by the European Medicines Agency50. In recent 
years the number of new treatments for ALS has increased considerably and some of these 
drugs are aimed at known mutations and pathogenetic pathways. Symptomatic therapies, 
including Tirasemtiv, are based on improving respiratory function in patients with ALS and 
are currently in Phase III; Phase I studies evaluating the use of antisense oligonucleotides in 
ALS related to SOD151 and C9orf72 are also ongoing52. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
 
2. Microglia 
During the course of many diseases, microglial cells lose their homeostatic molecular 
signature and function and become chronically inflammatory.  
 
2.1 Historical features 
It was Pio del Rio-Hortega in 1932 that first introduced the concept of microglia in a book 
chapter called “Microglia”53, even if these cells had already been identified in the early 20th 
century by Ramon y Cajal, that in 1913 described the “third elements” of SNC. In his 
article,del Rio-Hortega stated notions that nowadays have become postulates, such as: - 
microglia has mesodermal origin and enter the brain during early development; these 
invading cells use vessels and white matter tracts as guiding structures for migration and 
enter all brain regions; they can assume a branched, ramified morphology in the mature 
brain (known today as the resting microglia); after a pathological event, these cells undergo 
a transformation, that let them acquire an amoeboid morphology;  these cells have the 
capacity to migrate, proliferate and phagocytize. Del Rio-Hortega called the newly 
discovered cell class microglia and the individual cell “microgliacyte”. In 1939 Kershman 
introduced the classification of the three classical microglia phenotypes: ramified, 
intermediate, amoeboid. For many years the field did not advance beyond these statements. 
The modern era of microglia research started in the late 1960s whit Georg Kreutzberg. He 
studied microglia responses to injury in tissue with an intact blood-brain barrier. His work 
also provided the possibility to distinguish between responses of intrinsic microglia and 
invading monocytes and helped to establish the concept that microglia is important for 
regeneration of the brain. Nowadays with the introduction of microglial cultures, the 
research made many strides and we are very close to understand the real function of these 
immune cells, considered as residing macrophages (the innate immune cells that are a 
homologue of brain microglia), of CNS. The origin of microglia has now been clearly 
defined and shown to relate to the early colonization of the CNS by mesodermal progenitors 
that arise from the yolk sac54,55,56. It is now recognized that monocytes and tissue 
macrophages are not, as had been previously proposed, microglia progenitors in either health 
or disease and that, in adulthood, microglia are an independent self-renewing 
population57,58,59. Human microglia turn over at a yearly median rate of 28% and live, on 
average, for 4.2 years. Thus, most of the microglial population is renewed several times over 
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the course of a lifetime60. In support of the importance of microglial self-renewal, a recent 
study demonstrated that the repopulated microglia that rapidly replenish the adult brain’s 
microglial population after microglial depletion are solely derived from the proliferation of 
residual microglia and not from newly generated progenitors61.It has been recently shown 
that microglia expresses not only specific markers like Cx3cr1, CD11b, Iba1 and F4/8062, 
but RNA-seq analysis identified a new set of microglia-specific markers in the healthy brain 
that include HexB, P2ry12, S100A8, S100A9, Tmem119, Gpr34, SiglecH, TREM2, and 
Olfml363. 
 
2.2 Physiological functions of microglia 
Microglia represent about 5-12% of total cells of CNS, being present throughout the brain, 
with different density and distribution64. Microglia functions are important at various stages 
of development from embryonic stages to adulthood and aging. These cells have three 
essential functions: (i) sense their environment, (ii) conduct physiological housekeeping, and 
(iii) protect against modified-self and non-self injurious agents. An important message is 
that there is no resting microglia. Their sensing, housekeeping, and protecting functions 
keep them constantly engaged, and most microglia in healthy brains are capable of 
performing such functions. Microglia studies have revealed that these cells have highly 
dynamic processes and continuously monitor their local environment65,66. It is estimated that 
the resident microglia can scan the entire brain parenchyma every few hours67,68, suggesting 
that they have homeostatic functions in the healthy brain during which they actively contact 
other neural components, including synaptic clefts, with their fine processes. ATP is likely 
one of many signals that mediate microglia–neuron communication, and microglial 
processes are rapidly attracted to the source of ATP release65. Microglia play a crucial role 
in synaptogenesis, trophic support, chemotaxis and neurogenesis. In order to shape neuronal 
circuits during development, microglia mediate synaptic and axonal pruning by 
phagocytizing inappropriate synaptic connections and axons69,70. Microglia mediate 
synaptogenesis at prenatal stages71, with the secretion of several factors, such as nerve 
growth factor (NGF), brain-derived neurotrophic factor (BDNF) and neurotrophin 3 (NT3),  
and also these cells promote learning- dependent synapse formation through the secretion of 
BDNF in mice72. It also been shown that microglia attract monocytes to the brain in a CC- 
chemokine ligand 2  (CCL2)-dependent fashion. These monocytes play an important role in 
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neuroinflammation. For example, in the SOD1 mice model of ALS, spinal microglia has 
been shown to recruit splenic monocytes expressing the CC-chemokine 2 receptor (CCR2) 
and high levels of 6C lymphocyte antigen (LY6C)73. In addition, microglial cells promote 
neurogenesis through phagocytosis of excessive neonate cells and through cytokine 
secretion. Most newly born cells in the developing nervous system undergo apoptotic death 
as they pass from neural progenitors to neuroblasts and are rapidly eliminated by microglia-
mediated phagocytosis74. In addition, during neurogenesis in the adult hippocampus, 
microglia act through apoptosis-coupled phagocytosis. 
 
2.3 Microglia in health and disease 
It is now accepted that, during the course of many diseases, dysregulation of microglia 
functions results in an imbalance that initiates or propagates neurodegeneration and these 
cells become chronically inflammatory. Infection, trauma, ischemia, neurodegenerative 
diseases, glioma or any disturbance or loss of brain homeostasis evoke rapid and radical 
changes in microglial cell shape, gene expression and, in general, in the functional behavior 
defined as “microglial activation”. Mature microglia have highly ramified processes, 
whereas during development, they adopt an ‘amoeboid’ morphology with larger, rounder 
cell bodies and shorter, thicker branches. These morphological features during development 
are accompanied by higher levels of phagocytic activity as well as by distinct gene 
expression and secretory profiles. Microglia exhibit both phenotypic and functional 
plasticity in healthy and diseased brains75-78. In peripheral macrophages, cell phenotypes 
have been determined by the varied expression of cell surface receptors by these cells79. 
Similarly to macrophages, microglial phenotypes were characterized by the presence of 
particular cell surface molecules and the expression of specific sets of cytokines and were 
classified as either M1-like (exhibiting pro-inflammatory signaling and neurotoxicity) or 
M2-like (participating in the resolution of inflammation)80. However, it is now clear that this 
simplistic view of microglial phenotypes does not adequately describe the complex 
physiology of microglial cells81. The characterization of microglial diversity has therefore 
been redefined with the help of newly developed technologies, including RNA-sequencing, 
quantitative proteomics and epigenetic studies. Microglial activation may start with an early 
emergency response, such as defense-oriented functions, to fight off an infection or to limit 
further damage after an injury. The activated population with an initially chosen program 
may eventually convert to repair-oriented support for tissue restoration. When discussing the 
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acquisition of different phenotypes, the functional heterogeneity of microglia has to be 
considered, too. Regional heterogeneity and segregation of specific microglia population in 
tissues and preparations were demonstrated by morphology, selective detection of 
constitutive or inducible mRNAs and proteins. Heterogeneity was also observed in 
microglia from the aging brain where surprising differences between individuals were 
found82,83. These differences could impact on development, normal functionality, as well as 
vulnerability to inflammation84. Reactive gliosis and neuroinflammation are hallmarks of 
several neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease 
(PD), amyotrophic lateral sclerosis (ALS), and frontal temporal dementia (FTD). 
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3. Microglia in ALS 
Microglia is one of the most important populations involved in Amyotrophic lateral, where 
signals from these CNS-resident immune cells initiate and sustain MN degeneration. 
 
3.1 Microglia: between neuroprotection and neurotoxicity 
Autopsies85 and PET imaging86 in the brains of live ALS patients have shown microglia 
expressing proinflammatory markers at sites of motor neuron injury. Genes that are 
commonly mutated in ALS include superoxide dismutase 1 (SOD1), C9orf72 and TAR 
DNA-binding protein (TARDBP)87. Cytoplasmic aggregation by mutated genes in neurons 
and glia of ALS patients, and release of the accumulated cytoplasmic mutant SOD1 
(mSOD1) to the extracellular space that can be taken up by other cells are common 
features88,89. Transgenic mice overexpressing human mutant SOD1 (mSOD) develop a 
progressive motor neuron disease similar to ALS7,90. In this transgenic model of familial 
ALS, some proinflammatory microglia are seen in the spinal cord before clinical disease 
develops, increase with disease progression, and persist into end-stage disease91. Yamanaka 
et al.,92 have shown how the expression of mSOD1 specific in microglia accelerates disease 
onset and a few years later Apolloni et al.,93 have shown how microglial activation 
contributes to neuronal death. Studies investigating the progression of the disease in ALS 
mice indicate that resident microglia also increase their number during disease progression94. 
In the early stages of the disease, microglia release neuroprotective molecules to prevent and 
contain neuronal degeneration. In particular, a trophic role for activated microglia has been 
suggested at early stages of the disease95. In the SOD1G93A mice, it was observed a 
decrease in microglia number in the entire SC at the pre-symptomatic age96. But with the 
disease progression, it has been shown that they become harmful, releasing neurotoxic 
factors NF-κ B-dependent97 and partly mediated by IL-1β98. Several studies have also 
provided information on the mechanisms driving the changes in microglial signature in 
ALS. ALS is associated with neuronal death and the activation of TREM2–ApoE signaling 
in microglia by apoptotic neurons. This signaling activates miR-155, which has been shown 
to be a pro-inflammatory signal. In fact, the genetic deletion of Apoe abrogated the 
induction of miR-155 in microglia and increased survival in SOD1 mice99. Given that many 
of the microglial changes observed in ALS were also observed in a mouse model of AD, it is 
assumed that there exists a microglial response common to different pathological processes. 
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Transgenic mice carrying the human C9orf72 gene, a hexanucleotide repeat expansion that 
is associated with ALS and frontotemporal dementia, show pathological features of ALS, 
without behavioral abnormalities or neurodegeneration100. Recent studies have shown in 
mice deficient in C9orf72, that microglia were strongly activated in the mutant with a higher 
production of TNF and IL-1 and defective maturation of phagosomes to lysosomes101. 
Further studies have shown that C9orf72 is required for normal microglial function and that 
impairment of capacity microglial elimination of the aggregated proteins by altering the 
maturation of phagosomes to lysosomes, an important step in the defense of the host, can 
contribute to neurodegeneration in patients with the C9orf72 expansion. Transgenic mice 
expressing inducible human TDP-43 (hTDP43) show a progressive loss of motor neurons 
but only slight microglial changes102. Unexpectedly, TARDBP was also found to regulate 
microglial phagocytosis. Following the suppression of the hTDP-43 transgene expression, 
microglia selectively eliminated the existing neuronal hTDP-43. When microgliosis was 
blocked during the early recovery phase using a CSF1R and c-Kit inhibitor, these mice 
failed to recover full motor function, suggesting a neuroprotective role for microglia. 
Interestingly, the conditional deletion of TDP43 in microglia led to increased β-amyloid 
clearance and leads to a greater loss of synapses103, this could partially explain the less 
frequent occurrence of Alzheimer disease among patients with ALS. These studies 
demonstrated non-cell-autonomous pathology of ALS and raised the possibility of targeting 
microglia for treating neurodegenerative diseases. 
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4. Intermediate Conductance Calcium-Activated Potassium Channels (KCa3.1) 
In the CNS, KCa3.1 channels are expressed by microglial cells, where they regulate cell 
migration and phagocytic activity in physiological and pathological conditions. 
 
4.1 Calcium-activated potassium channels: properties 
Ion channels are involved in several physiological and pathological cellular functions, and in 
hallmarks of cancer cell aggressiveness, such as proliferation and migration. In most cases, 
their contribution consists in regulating two important cellular parameters, the cell volume 
and the intracellular Ca2+ concentration ([Ca2+]i)104,105. Modulation of these two parameters, 
in addition to the ClC-3 channels, requires the activity of Ca2+-activated K-selective BK 
channels, often markedly upregulated in glioblastoma cells106,107. Ca2+ influx through the 
TRPC family of Ca2+-permeable channels has indeed been shown to modulate glioblastoma 
cell cycle progression108 and to induce a Ca2+/calmodulin-dependent protein kinase II 
(CaMKII)-dependent activation of ClC-3 during premitotic volume condensation109. In 
addition, glioblastoma cell migration has been shown to be accompanied by intracellular 
Ca2+ oscillations that are instrumental to promote the kinase-dependent detachment of focal 
adhesions during cell rear retraction110 and these intracellular Ca2+ oscillations can be 
significantly affected by the membrane hyper-polarization determined by the activity of K+ 
channels111.Ca2+-activated K+ (KCa) channels are at the crossroad where Ca2+ influx, 
membrane potential, and outward ion fluxes, integrate to modulate a large array of cellular 
processes112. The human genome contains eight KCa channels, which can be divided into 
two groups depending on their genetic relationship, their single channel conductance and the 
molecular mechanism of their Ca2+ sensitivity113. The first group encompasses KCa1.1, 
KCa4.1, KCa4.2 and KCa5.1, which were initially grouped together based on structural 
similarity but later found to differ in their activation mode. While the founding member of 
the group, KCa1.1, is indeed a true KCa channel and is activated by Ca2+ binding to a 
negatively charged segment in the C-terminus, KCa4 and KCa5 channels are activated by 
Na+, Cl- or alkalization113. The second group consists of the three small-conductance 
channels, KCa2.1 (SK1), KCa2.2 (SK2) and KCa2.3 (SK3), and the intermediate-
conductance channel KCa3.1 (IK1, SK4) (Figure 1)121. KCa3.1 was cloned by three 
independent groups in 1997114,115 and has approximately 42-44% sequence identity to the 
KCa2 channels. Like the KCa2 channels, KCa3.1 is voltage independent and is activated by 
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350 nM intracellular Ca2+ binding to the EF-hands of calmodulin, which is constitutively 
associated with the C-terminal region and serves as its Ca2+-sensing-subunit116. 
 
 
 
              Wulff H et al., Expert Rev Clin Pharmacol (2010) 
Figure 1. Properties of KCa3.1 channels. A. Simplified phylogenetic tree of genes for human potassium 
channel subunits, highlighting in red the two gene families that comprise Ca2+-activated potassium channels 
and further highlighting the KCNN family which contains the gene for KCa3.1 (KCNN4). B. Illustration of 
KCa3.1 subunit topology showing the six transmembrane domain signature of this class of channels, along 
with calmodulin attached to a calmodulin binding domain on the C terminus. The location of the histidine 
phosphorylation site (H358) known to affect channel activation is also shown. C. Illustration of the homo-
tetrameric nature of functional KCa3.1 channels, showing the presence of four calmodulin calcium sensors 
which accounts for the channel’s steep, highly cooperative sensitivity to changes in intracellular calcium 
concentration. 
 
KCa3.1 gene transcription can be repressed by the repressor element-1 silencing 
transcription factor117 and increased through the transcription factors activation protein 1 
(AP-1) and Ikaros-2118. KCa3.1 function is increased by protein kinase A119 and nucleoside 
diphosphate kinase B and inhibited by the histidine phosphatase PHPT1120. Nucleoside 
diphosphate kinase B and PHPT1 directly exert their activity on histidine 358 at the C-
terminus and KCa3.1 modulation thus constitutes one of the rare examples of histidine 
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kinase/phosphatase regulating a biological process in mammals. Clotrimazole and its 
derivative TRAM-34 are potent and selective inhibitors of KCa3.1. KCa3.1 channels are 
expressed in a variety of normal and tumor cells, where they participate in important cell 
functions such as cell cycle progression, migration, and epithelial transport, by controlling 
the cell volume and the driving force for Ca2+ influx121. Importantly, TRAM-34 has been 
already used in several in vivo studies aimed at attenuating restenosis after angioplasty122, in 
atherogenesis123, in EAE124, in cerebral stroke125 and other diseases. Another KCa3.1 
blocker, ICA17043, has been used in clinical trials for sickle cell anemia and exercise-
induced asthma and these trials support KCa3.1 as a safe therapeutic target, with no evident 
adverse effects even upon long-term use126. 
 
4.2 Physiological role of KCa3.1 
Interesting roles for ion channels in basic biological functions, such as growth control, cell 
differentiation and migration emerged in studies on normal127 and malignant cells104,128. 
Glioma cells use ion channels (mainly K+ and Cl-), to generate an osmotic gradient for 
cytoplasmic water flux, thereby altering cellular volume129. Important volume changes 
precede each cell division as glioma cells retract their processes, condense and round up to a 
sphere130. Cell rounding requires the release of cytoplasmic water, accomplished by the 
coordinated secretion of potassium chloride (KCl) with osmotically obligated water. 
Outward directed gradients for K+ and Cl- are established by the activity of the Na+/K+-
ATPase and the sodium-potassium-chloride cotransporter isoform-1 (NKCC1), respectively. 
Intracellular Cl- reaches concentrations of 100-140 mM, approximately ten-fold higher than 
that of neurons and other cells131. The condensation engages chloride channel-3 (ClC-3)-
type channels, which are activated through Ca2+-dependent phosphorylation by 
Ca2+/CaMKII 132. K+ efflux occurs via Ca2+-activated K+ channels133 and water leaves 
through aquaporins130. This highly orchestrated interplay of ion transporters and ion 
channels allows a cell to condense its cell volume rapidly, within approximately 40 minutes, 
facilitating the pre-mitotic rounding133. Similar volume changes occur as gliomas invade the 
brain through narrow extracellular passageways along white matter tracts or blood vessels. 
To navigate the tortuous extracellular brain spaces, glioma cells dynamically adjust their 
volume. On encountering barriers too narrow to pass, cells quickly reduce their volume by 
approximately 33%, regardless of the size of the barrier. Cell shrinkage is achieved by the 
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efflux of Cl- ions along with essentially all unbound cytoplasmic water and maximizes the 
chance of the cell to advance past a barrier. This volume reduction utilizes the same Cl- and 
K+ channels described above130 and these channels are activated downstream of intracellular 
Ca2+ increases originating from the activation of AMPARs, bradykinin receptors134 or 
transient receptor potential channels (TRPC)135. The above-described cell volume changes 
associated with cell migration suggest several new possible pharmacological targets to 
interfere with glioma invasion. For example, the diuretic bumetanide (Bumax) inhibits 
intracellular Cl- accumulation in glioma cells and, in a mouse model, reduced the ability of 
gliomas to invade and generate satellite tumors136. In preclinical studies, the 
pharmacological inhibition of Cl- channels or genetic downregulation of ClC-3 reduced the 
ability of gliomas to invade137. Furthermore, the Cl- channel inhibitor, chlorotoxin, has been 
used in phase I/II clinical study in patients with glioma138. Additionally, the regulators of 
channels and transporters, such as CaMKII, which regulates ClC-3 KCa2+ channels, or the 
with-no-lysine kinase-3 (WNK3), which regulates139, may be promising additional targets. It 
must be emphasized that the hydrodynamic model of glioma invasion assumes that ion 
channels participate in a facilitator role. Given that cell invasion constitutes a complex and 
highly coordinated biology, the disruption of only one pathway may not be sufficient to 
derail the process but could be the first step to build a new combinatorial strategy to 
counteract glioma cell infiltration in the healthy parenchyma. 
 
4.3 Microglial ion channels 
In all living cells, ion channels are required to regulate the membrane potential and 
intracellular ion concentrations. Functional ion channels allow movements of cations or 
anions across the membrane, which subsequently may influence a variety of cellular 
processes, such as proliferation, excitability, migration, apoptosis, secretion and others. Ion 
channels are specialized membrane proteins that span the plasma membrane. They form 
hydrophilic pores through which ions flow from one side of the membrane to the other down 
their electrochemical gradient. Microglial ion channels have been studied using the patch 
clamp technique. Ion channels can be distinguished based on their ion selectivity, 
conductances, gating properties, kinetics and pharmacology. Within the CNS, substantial 
changes in extracellular pH and ion concentrations occur during neuronal activity. For 
example, the external concentration of potassium increases during neuronal activity and can 
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be largely augmented under pathological conditions. Changes in the extracellular milieu can 
dramatically alter the activity of microglial ion channels and subsequently induce changes in 
microglial functioning and activation. 
 
4.4 Role of KCa3.1 in microglial cells 
Many studies on microglial electrophysiology focused on K+ channels: potassium channels 
are involved in the regulation of resting potential regulating the majority of their function, 
such as phagocytosis, antigen presentation, motility, cytokine secretion and others. 
Many physiologically active substances increase the concentration of intracellular Ca2+, 
leading to the activation of Ca2+-activated K+ channels. These channels are involved in the 
control of microglia activation and contribute to the upregulation of iNOS and the 
production of NO and peroxynitrite, directly implicated in neurotoxicity and linked to the 
activation of mitogen-activated protein kinase (MAPK) cascade140. 
Different brain insults differentially activate microglia; the activation process requires the 
ability of microglia to change its shape to exert various functions and, as in other cells, also 
microglia regulate cell shape modulating the concentrations of different ionic species at their 
inner, trough K+ channels. Also in microglia, KCa3.1 channels are related to different 
downstream processes, such as migration, activation of specific pathways and 
neurotoxicity141,142. In most cases, the block of KCa3.1 has been shown able to contrast 
cerebral damage143 associated with pathologies leading to a reduction of the microglia 
neurotoxic potential140. These important findings raise the awareness that these peculiar 
channels could be considered as optimal targets for the development of drugs against brain 
diseases, acting on microglia activation state. Microglia, in fact, is the only cell type 
expressing KCa3.1 channels in the CNS141 and the activation of the related current is often 
considered as a microglia activation parameter144. Recently, it has been demonstrated that, 
upon KCa3.1 inhibition by 1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole (TRAM-34), 
the glioblastoma multiforme (GBM)- or IL-4-induced profile of microglia/macrophages 
(M/MΦ) is more polarized toward an inflammatory phenotype. This effect is confirmed, ex 
vivo, in human specimens from glioma patients and, in vivo, in a mouse model of glioma, 
where TRAM-34 treatment induced an increase of pro-inflammatory and a reduction of anti-
inflammatory gene expression in infiltrating CD11b+ cells. This polarization corresponded 
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to a reduced tumor size in TRAM-34-treated glioma-bearing mice, further supporting the 
antitumor effect of inflammatory M/MΦ cells145. 
 
 
4.5 KCa3.1 blockers are relatively safe 
TRAM-34 (IC50 20 nM) is currently the most widely used pharmacological tool compound 
for studying the pathophysiology of KCa3.1 because of its high selectivity over other 
K+ channels. It was synthesized by Wulff et al.146 using as a template the antimycotic 
clotrimazole, which is a potent but poorly tolerated KCa3.1 inhibitor. KCa3.1 blockers are 
very light immunosuppressants that do not reduce the ability of rodents to eliminate viral 
infections like influenza147. Furthermore, genetic or pharmacological block of KCa3.1 seems 
relatively safe and well tolerated. KCa3.1 -/- mice were both vital, of normal appearance and 
normal size of puppies, done do not show any serious anomaly in any of their principal 
organs, and exhibited rather mild phenotypes: altered volume regulation in erythrocytes and 
lymphocytes147, a reduced EDHF (hyperpolarization derived from the endothelium factor), 
along with a slight increase of ~ 7 mmHg in blood pressure148 and in thin macrocytosis of 
erythrocyte and progressive splenomegaly149. It has been reported that TRAM-34 has 
previously been tested for long-term toxicity in mice and rats. In WT C57BL/6L mice, 4 
weeks of treatment with 120 mg/kg TRAM-34 i.p. did not induce any changes in body 
weight, hematology, blood chemistry or necropsy of any major organs. Similarly, treatment 
of ApoE-/- mice for 3 months did not induce any changes in the body weight, heart weight, 
blood pressure or heart rate123. In male and female Lewis rats, a 6 months toxicity study with 
120 mg/kg TRAM-34 did also no induce any changes in body weight, hematology, blood 
chemistry, necropsy, or increase the susceptibility to infections150.  
Senicapoc, molecule structurally related to TRAM-34, which advanced into Phase-3 clinical 
trials, has been proven safe and well tolerate in healthy volunteers. It was afterward found to 
significantly reduce hemolysis and increase hemoglobin levels in a 12-week, multicenter, 
randomized double-blind Phase-2 study in sickle cell disease patients151,152.  
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A B S T R A C T
Recent studies described a critical role for microglia in amyotrophic lateral sclerosis (ALS), where these CNS-
resident immune cells participate in the establishment of an inflammatory microenvironment that contributes to
motor neuron degeneration. Understanding the mechanisms leading to microglia activation in ALS could help to
identify specific molecular pathways which could be targeted to reduce or delay motor neuron degeneration and
muscle paralysis in patients. The intermediate-conductance calcium-activated potassium channel KCa3.1 has been
reported to modulate the “pro-inflammatory” phenotype of microglia in different pathological conditions. We here
investigated the effects of blocking KCa3.1 activity in the hSOD1G93AALS mouse model, which recapitulates many
features of the human disease. We report that treatment of hSOD1G93A mice with a selective KCa3.1 inhibitor, 1-
[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole (TRAM-34), attenuates the “pro-inflammatory” phenotype of mi-
croglia in the spinal cord, reduces motor neuron death, delays onset of muscle weakness, and increases survival.
Specifically, inhibition of KCa3.1 channels slowed muscle denervation, decreased the expression of the fetal
acetylcholine receptor γ subunit and reduced neuromuscular junction damage. Taken together, these results de-
monstrate a key role for KCa3.1 in driving a pro-inflammatory microglia phenotype in ALS.
1. Introduction
Amyotrophic lateral sclerosis (ALS) is a multifactorial disease
characterized by the progressive degeneration of motor neurons (MN)
and muscle paralysis. Despite current treatments, patients survive<
3–5 years after the initial diagnosis. Most ALS cases are sporadic
(sALS), and only 5–10% have a familial origin (fALS). Among the latter,
about 20% express a dominant mutant form of the Cu, Zn superoxide
dismutase (SOD1) (Rothstein, 2009). Transgenic mice expressing a
mutant SOD1 develop MN pathology, with muscle denervation and
weakness similar to ALS patients (Fischer et al., 2004). Many evidence
demonstrate that ALS is non-cell autonomous, with multiple co-players
involved in disease progression (Robberecht and Philips, 2013). In
particular, signals from both glial cells and muscles initiate and sustain
MN degeneration (Boillée et al., 2006; Dobrowolny et al., 2008). Neu-
roinflammation is often associated with ALS (Philips and Robberecht,
2011): microglial reactivity, astrogliosis and lymphocyte infiltration are
common in patients and in experimental models of the disease (Hall
et al., 1998; Mantovani et al., 2009; Turner et al., 2004). Microglia
carrying mutant SOD1 express pro-inflammatory genes, such as il-1β,
tnf-α and inos (Philips and Robberecht, 2011; Almer et al., 1999; Henkel
et al., 2004). Nevertheless, the exact contribution of neuroinflammation
to the pathology of ALS is not clear, possibly acting in concert with
additional factors. The knowledge of the molecular mechanisms driving
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T
the inflammatory responses, and their impact on MN, would be of great
importance to develop effective therapeutic treatments. Among the
possible modulators of the inflammatory response in the CNS, plasma
membrane ion channels are good candidates, regulating membrane
potential and intracellular signaling in T cells, B cells and innate im-
mune cells such as macrophages and microglia (Feske et al., 2015;
Zierler et al., 2016). In this work, we investigated the role of the in-
termediate-conductance, Ca2+-activated K+ channel KCa3.1, in
shaping the activation state of microglia in a mouse model of ALS, the
hSOD1G93A mice, which recapitulates many features of the human
disease. In the CNS, KCa3.1 channels are expressed by microglial cells,
where they regulate cell migration and phagocytic activity in physio-
logical and pathological conditions such as glioma, ischemia, spinal
cord injury (SCI) and Alzheimer’s disease (AD) (Chen et al., 2011;
Maezawa et al., 2012; Bouhy et al., 2011; D’Alessandro et al., 2013;
Grimaldi et al., 2016). In some conditions (SCI), the expression of
KCa3.1 is also reported on astrocytes and neurons (Bouhy et al., 2011).
In AD, microglial KCa3.1 potentiate the neurotoxicity induced by oli-
gomeric amyloid-β and lipopolysaccharide (LPS) treatment (Maezawa
et al., 2012; Kaushal et al., 2007); while blocking KCa3.1 activity has
beneficial effects in rodent models of multiple sclerosis and ischemic
stroke, reducing TNF-α and IFN-γ expression in the spinal cord (Reich
et al., 2005) or the infarcted area (Chen et al., 2016). The KCa3.1 in-
hibitor per se is not directly neuroprotective in the absence of microglia
(Maezawa et al., 2011; D’Alessandro et al., 2016).
In the current study, we treated hSOD1G93A mice with the selective
KCa3.1 inhibitor TRAM-34 starting at the pre-symptomatic stage and
analyzed the activation state of spinal cord microglia by measuring the
expression levels of “pro“ and “anti-inflammatory” genes and cell
morphology. We found that the chronic inhibition of KCa3.1 activity in
hSOD1G93A mice: i) restrained the pro-inflammatory phenotype of mi-
croglia; ii) increased the number of healthy MNs; iii) preserved the
number of healthy neuromuscular junctions (NMJ) in the tibialis ante-
rior muscle; iv) and their maturation level, as assessed by mRNA ana-
lysis of AChR γ and ε subunit expression and by current recording on
isolated muscle fibres. Furthermore, TRAM-34 treatment delayed motor
symptom appearance, as shown by prolonged muscle strength and
motor coordination, and increased mice survival. Taken together, these
data demonstrate a crucial role for microglia in modulating disease
onset and progression, and provide prove-of-concept for the potential
targeting of KCa3.1 to reduce ALS-associated neuroinflammation and to
protect MNs from degeneration.
2. Materials and methods
2.1. Animal model
The study was conducted in accordance with the ARRIVE guidelines
(Kilkenny et al., 2010). All experiments and procedures were approved
by the Italian Ministry of Health (authorization n. 78/2017-PR) in ac-
cordance with the ethical guidelines on use of animals from the EC
Council Directive 2010/63/EU and from the Italian D.Leg 26/2014. All
possible efforts were made to minimize animal suffering, and to reduce
the number of animals used per condition by calculating the necessary
sample size before performing the experiments. hSOD1(G93A) trans-
genic mice, which express about 20 copies of mutant human SOD1G93A
[B6.Cg-Tg(SOD1-G93A)1Gur/J line] were obtained from Jackson La-
boratory (Bar Harbor, ME, USA) (RRID:IMSR_JAX:004435) (Charles
River, Calco, Italy). B6.Cg-Tg(SOD1-G93A)1Gur/J were also main-
tained as hemizygotes by breeding transgenic males with wild-type
C57BL/6J females from Charles River Laboratories, both maintained on
C57BL/6J genetic background. Age-matched non-transgenic C57BL/6J
mice were always used as control mice. Only male mice were used for
the experiments to minimize gender-induced differences in motor im-
pairment and survival (Choi et al., 2008). Transgenic mice were iden-
tified by PCR on DNA obtained from tail biopsies. Briefly, tail tips were
digested (overnight, 58 °C) in a buffer containing 100mM Tris–HCl pH
8, 0.1% SDS 20, 5mM EDTA pH8, 200mM NaCl and 20mg/ml pro-
teinase K (Ambion-Thermo Fisher, Germany, #2548) and the genomic
DNA was amplified with SsoFast Eva Green Supermix (Bio-Rad, Cali-
fornia, #172-5201) using the following primers: SOD1 forward
5′-CATCAGCCCTAATCCATCTGA-3′; SOD1 reverse 5′- CGCGACTAACA
ATCAAAGTGA-3′. Animals were housed in regular polycarbonate cages
(30×16×11 cm), 2–3 per cage, at constant temperature (22 ± 1 °C)
and humidity (50%), and were kept on a 12-h light cycle (light 7 a.m.to
7p.m.). Housing comprised nesting objects, with bedding (sawdust)
materials. Food (regular chow, containing 14% protein, 5% fat,
3041 kcal ME/kg) and water were freely available. Microbiological
analyses were routinely (each 3–4months) performed and defined en-
demic Norovirus and Helicobacter in our conventional animal facility.
Transgenic animals were weighed two times a week, beginning at
7 weeks of age. Starting at 6 weeks of age mice were evaluated for
motor deficits with a behavioral score system: 0= Full extension of
hind legs away from the lateral midline when the mouse is suspended
by tail; the mouse must hold this position for 2 s, and is suspended 2–3
times; 1=Collapse or partial collapse of leg extension towards lateral
midline (weakness) or trembling of hind legs during tail suspension;
2=Curling of the toes and dragging of at least one limb during
walking; 3=Rigid paralysis or minimal joint movement; foot not used
for forward motion; 4=Mouse cannot stand up in 20 s from either side,
euthanasia.
Mice were always treated in blinded fashion.
2.2. TRAM-34 treatment and survival analysis
Male transgenic animals were weighed twice a week from 6 until
18 weeks of age. Then, the animal status and weight was monitored
daily. Starting at 7 weeks of age, hSOD1G93A mice were randomly
grouped (at least 5 mice per experimental group) for vehicle and
TRAM-34 (1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole treat-
ment. Mice were treated daily (early in the morning) with 120mg/kg of
TRAM-34 or the same amount of vehicle (50 μl, peanut oil, Sigma-
Aldrich, St. Louis, MO USA, #P2144) by intraperitoneal injections. The
treatment regimen was chosen to reach a CNS concentration of TRAM-
34 that effectively inhibits KCa3.1 channels, as previously described
(D’Alessandro et al., 2013). TRAM-34 was synthesized as described
(Wulff et al., 2000). Animals were treated until the age described in the
text or until sacrifice for the survival analysis experiments. Animals
were sacrificed when unable to stand up within 20 s after being placed
on either side.
2.3. Isolation of lumbar microglia cells
Adult microglia were isolated from the lumbar spinal cord tract of
age-matched non-transgenic C57BL/6J wt mice (non-tg wt) and
hSOD1G93A mice as described in (Yip et al., 2009) with minor mod-
ifications. Mice were deeply anesthetized with chloral hydrate (i.p.,
400mg/Kg, Carlo Erba Italy, #334085) before being transcardially
perfused with phosphate buffered-saline (PBS tablet, Sigma-Aldrich,
#P4417). Spinal cords were then flushed out from the spinal canal
using a 20ml syringe filled with PBS and digested with 30 units of
papain (15–23 U/mg protein, Sigma-Aldrich, #P3125) for 30min at
37 °C. Tissue was then triturated with a pipette to obtain single cell
suspensions, which were applied to 70-μm/40-μm cell strainers and
used for the experiments. Purity of isolated microglia was assessed by
morphology and surface staining for CD11b+, CD45low+, Ly6G-,
Ly6C−. mAbs directly conjugated to PE, PE-Cy7, APC, APC-H7, and
PerCP-Cy5.5 fluorochromes and specific for the following antigens
(clone name in parentheses) were used: CD45 (1 0 4), CD11b (M1/70),
Ly6C (HK1.4), and Ly6G (1A8). Antibodies were from eBioscience
(Thermo Fisher, Germany) and BioLegend (San Diego, CA). Im-
munostaining was performed with saturating amounts of Abs for 30min
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at 4 °C. Purity of isolated microglia cells ranged between 70 and 90 %,
as verified by flow cytometry.
2.4. ROS production
Microglia from the lumbar spinal cord of non-tg wt mice were
treated for 18 h with 5 μM of sodium azide (Acros, part of Thermo
Fisher, Germany #190381000) in presence or absence of 2.5 μM of
TRAM-34. To evaluate ROS production, cells were extensively washed
and incubated with 10 μM of 2′,7′-Dichlorodihydrofluorescein diacetate
(DCF, Sigma-Aldrich, #D6883) for 30min at 37 °C. Cell fluorescence
was detected in FL1 channel and analyzed with a FACSCanto II (BD
Biosciences). Data were analyzed using FlowJo v9.3.2 software
(TreeStar, Ashland, OR, USA).
2.5. Isolation of embryonic mouse MN
MN cultures were obtained from E13 C57BL6/J mice. Pregnant fe-
males were euthanized by cervical dislocation and the spinal cords were
removed from embryos; tissues were digested with 0.25% Trypsin in
Neurobasal medium at 37 °C. After 20min the reaction was stopped by
adding trypsin inhibitor and pipetting 10–15 times with a glass Pasteur
pipette, until no more cell aggregates were visible. Cells were kept
15min at RT on a vibration-free surface and centrifuged at 1200 rpm
for 10min; the pellet was resuspended in complete Neurobasal medium
(Gibco, part of Thermo Fisher, Germany #10888-022) (2 mM gluta-
mine, 1% B27, 100 U/ml penicillin and 0.1 mg/mL streptomycin) and
plated (2×105 cells/well) onto poly-L-lysine coated glass cover slips.
After nine days in culture, embryonic mouse MNs (2×105 cells/well)
were co-cultured with adult microglia (non-tg wt pre-treated with 5 μM
sodium azide (NaN3) or hSOD1G93A microglia) plated (105 cells/well)
on poly-L-lysine-coated transwells (Corning, Sigma-Aldrich, USA,
0.4 μm pore size).
2.6. Microglia/MN co-cultures
Co-cultures were treated with the following: 2.5 μM TRAM-34, or
DMSO (0.01%, Sigma-Aldrich, USA) as vehicle. After 72 h of co-culture,
MN death was measured by immunofluorescence staining using acti-
vated caspase 3 antibody (Cell Signaling, Danvers, USA #9661, 1:400),
as apoptotic marker, and non-phosphorylated neurofilament H anti-
body (SMI32 clone, Biolegend, #801701, 1:500), as MN marker. Only
double positive cells were counted as dead cells; this number was
normalized to the mean of SMI32-positive cells counted in each well.
2.7. Real-time PCR
Total RNA was extracted from lumbar microglia, muscle fibres of
non-tg wt, vehicle and TRAM-34-treated hSOD1G93A mice following a
standard Trizol (Invitrogen, CA, #T9424) protocol, quantified with
NanodropOne (Thermo Scientific) and retro-transcripted using IScript
Reverse Transcription Supermix (Bio-Rad, #1708841). RT-PCR of genes
described was carried out in a I-Cycler IQ Multicolor RT-PCR Detection
System (Bio-Rad, #172-5201) using SsoFast Eva Green Supermix (Bio-
Rad). Relative gene expression was calculated by ΔΔCT analysis relative
to GAPDH expression levels. GAPDH: forward (F), 5′-TCGTCCCGTAG
ACAAAATGG-3′, reverse (R), 5′-TTGAGGTCAATGAAGGGGTC- 3′; IL-
1β: F, 5′-GCAACTGTTCCTGAACTCAACT-3′, R, 5′-ATCTTTTGGGGTCC
GTCAACT-3′; BDNF: F, 5′-CGGC GCCCATGAAAGAAGTA-3′, R, 5′-AGA
CCTCTCGAA CCTGCCCT-3′; ARG1:(F), 5′- CTCCAAGCCAAAGTCCTTA
GAG-3′, (R) 5′- AGGAGCTGTCATTAGGGACATC-3′; CD163:(F), 5′-
TCTGGCTTGACAGCGTTTC-3′, (R) 5′- TGTGTTTGTTGCCTGG
ATT-3′;FIZZ:(F),5′-CCAATCCAGCTAACTATCCCTCC-3′, (R) 5′- ACCCA
GTAGCAGTCATCCCA-3′;IL-6:(F),5′-GATGGATGCTACCAAACTGGA-3′,
(R) 5′-TCTGAAGGACTCTGGCTTTG-3′;INOS:(F), 5′-ACATCGACCCGTC
CACAGTAT-3′, (R) 5′- CAGAGGGGTAGGCTTGTCTC-3′;TNF-a:(F),
5′-GTGGAACTGGCAGAAGAG-3′, (R) 5′- CCATAGAACTGATGAG
AGG-3′;YM1:(F), 5′-CAGGTCTGGCAATTCTTCTGAA-3′, (R) 5′- GTCTT
GCTCATGTGTGTAAGTGA-3′; myogenin (F) 5′-GCACTGGAGTTCGGTC
CCA-3′, (R) 5′-GTGATGCTGTCCACGATGGA-3′; atrogyn-1 (F) 5′-GCAG
CAGCTGAATAGCATCCA-3′, (R) 5′-GGTGATCGTGAGGCCTTTGAA-3′;
AChRγ (F) 5′-GCTCAGCTGCAAGTTGATCTC-3′, (R) 5′-CCTCCTGCTCC
ATCTCTGTC-3′; AChRε 5′- GCTGTGTGGATGCTGTGAAC-3′, (R)
5′-GCTGCCCAAAAACAGACATT-3′; kccn4 (F) 5′-GGCTGAAACACCGG
AAGCTC-3′, (R) 5′-CAGCTCTGTCAGGGCATCCA-3′.
2.8. Behavioral tests
Mice were housed in standard breeding cages at a constant tem-
perature (22 ± 1◦C) and relative humidity (50%), with a 12:12 h
light:dark cycle (light on 07.00–19.00 h). Food and water were avail-
able ad libitum. Behavioral tests started when mice were 7 weeks old.
All animals were handled for at least 5 min/day for 2–3 days before
starting the experiments.
2.8.1. Inverted grid test
Mice were placed in the center of a wire grid (40× 60 cm, sus-
pended 50 cm above a cushioned table) and then the grid was inverted
(maximum time allowed 60 s). The time spent hanging on to the grid
was measured. (Rinaldi et al., 2013)
2.8.2. Hindlimb extension reflex
Mice were suspended by the tail, and scored for hindlimb extension
reflex deficits. The scores were recorded from 0 to 2 as follows: 2,
normal extension reflex in both hind limbs; 1.5, imbalanced extension
in the hind limbs; 1.0, extension reflex in only one hindlimb; 0.5, the
absence of any hindlimb extension; and 0, total paralysis. (Ludolph
et al., 2010)
2.8.3. Hanging wire test
To perform this test, mice were allowed to grab a horizontal wire
with their front paws and the time spent hanging measured (maximum
time allowed 60 s). Behavior was scored according to the following
scale: 1, hanging onto the bar with both forepaws; 2, in addition to 1,
attempted to climb onto the bar; 3, hanging onto the bar with two
forepaws and one or both hindpaws; 4, hanging onto the bar with all
four paws with tail wrapped around the bar; 5, able to walk on the bar
to escape. (Rinaldi et al., 2013)
2.8.4. Rotarod test
Motor coordination, strength and balance were assessed using a
rotarod apparatus (Ugo Basile, Gemonio Italy, #47650). Animals were
placed onto the cylinder at a constant speed of 15 rpm. The arbitrary
cut-off time was 300 s., and the longest latency was recorded.
2.8.5. Grip strength test
The apparatus consisted of a grip strength meter (Ugo Basile,
#47200), complete with a force transducer and a grasping device (grid
for measurement of the four limbs). The mouse was held at the base of
the tail and allowed to grab the grid with either four limbs. The mouse
was then pulled gently backwards until it released its grip. The peak
force of each trial was taken as a measure of the grip strength.
2.9. Immunofluorescence
Spinal cord slices were prepared from hSOD1G93A and non-tg wt
mice treated with vehicle or TRAM- 34 as described. Spinal cord sec-
tions (20 μm) were washed in PBS, blocked (3% goat serum in 0.3%
Triton X-100) for 1 h, at RT, and incubated overnight at 4 °C with
specific antibodies diluted in PBS containing 1% goat serum and 0.1%
Triton X-100. The sections were incubated with the following primary
Abs: Iba1 (Wako, Osaka Japan, #019-19741, 1:500), GFAP (Novus
G. Cocozza et al. Brain, Behavior, and Immunity 73 (2018) 584–595
586
Biologicals, Littleton USA, #NB300-141, 1:500), SMI-32 (BioLegend,
1:500) and cleaved caspase-3 (Cell Signaling, 1:400). After several
washes, sections were stained with the fluorophore-conjugated anti-
body and Hoechst for nuclei visualization and analyzed using a fluor-
escence microscope. For Iba1/SMI-32 staining, coronal sections were
first boiled for 20min in citrate buffer (pH 6.0) at 95–100 °C.
Quantification of Iba1 and GFAP immunoreactivity was performed
on lumbar spinal cord sections (12 serial coronal sections for each an-
imal, in each group, covering the entire L3-L5 segments), using
MetaMorph 7.6.5.0 image analysis software (Molecular Device, San
Jose USA), after background subtraction. Iba or GFAP im-
munoreactivity was measured as the ratio of the area occupied by
fluorescent cells (thresholded area) versus the total ventral horn area.
At least 5 animals per condition were analyzed.
Images were digitized using a CoolSNAP camera (Photometrics,
Tucson USA) coupled to an ECLIPSE Ti-S microscope (Nikon, Tokio
Japan) and processed using MetaMorph 7.6.5.0 image analysis software
(Molecular Device, San Jose USA). Signal co-localization was analyzed
measuring the average fluorescence intensity (pixel) of merged signals.
2.10. Motor neuron survival evaluation
For MN survival, the whole ventral horns of lumbar spinal cord were
photographed at× 20 magnification and digitized using a CoolSNAP
camera (Photometrics) coupled to an ECLIPSE Ti-S microscope (Nikon)
and processed using MetaMorph 7.6.5.0 image analysis software
(Molecular Device). The number of MNs was evaluated counting only
SMI32-positive cells with typical morphology triangular shape, single
well-defined axon, large body diameter (≥20 μm) and intact axons and
dendrites. This was done in 12 serial slices for each animal and data
normalized with respect to non-tg wild-type mice, where the number of
healthy MNs was taken as 100%.
2.11. Skeleton analysis
Microglia from sections of lumbar ventral horns were analyzed by
confocal microscopy using IBA1 signal and skeletonized to assess cell
morphology. Twenty μm z-stacks were acquired at 0.5 μm intervals
using an FV10i laser scanning microscope (Olympus, Tokyo Japan) at
×60 objective. Cell morphology was measured using a method adapted
from Morrison and Filosa, 2013. Maximum intensity projections for the
IBA1 channel of each image were generated, binarized, and skeleto-
nized using the Skeletonize 2D/3D plugin in ImageJ, after which the
Analyze Skeleton plugin (http://imagej.net/AnalyzeSkeleton) was ap-
plied. The average branch number (process end points per cell) for each
image with a voxel size exclusion limit of 150 was applied. The number
of single and multiple junction points was additionally calculated to
give an indication of branching complexity. The areas of the soma and
the scanning domain, defined as the perimeter within which individual
cells project their dynamic processes, were measured for each cell.
2.12. Fibre preparation
Fibres were obtained from the FDB muscles of hSOD1G93A and non-
tg wt mice hind-limbs. The dissected muscles were incubated with Type
I collagenase (2 mg/ml, Sigma) for 45min at 37 °C in MEM (Gibco,
#11095-080) digestion medium (Sodium Pyruvate 1mM+FBS
0.2%+Pen Strep 2%, Sigma). After equilibrating in S-MEM (Gibco,
#11380-037) Ca2+ -free dissociation medium (Sodium Pyruvate
1mM+FBS 0.5%+Pen Strep 2%+HEPES 20mM, Sigma) for 15min
at 37 °C, the muscle fibres were mechanically dissociated using fire
polished glass pipettes and P100 micropipette. For recordings, a bunch
of single fibres was transferred on ECM (3.33mg/mL, Sigma-Aldrich,
USA) coated glass slide and incubated at 37 °C for 15min. The fibres
remained viable for at least 4–5 h.
2.13. Neuromuscular junction evaluation
Mice treated as above were deeply anaesthetized before being
transcardially perfused with PBS. Tibialis anterior muscles were dis-
sected out and snap-frozen in cooled isopentane. Muscles were gently
stretched on a Sylgard coated Petri dish and fixed with paraformalde-
hyde 4% in PBS for 60min at RT. For AChR staining, the fixed muscles
were incubated with rhodamine-conjugated alpha-bungarotoxin (6mg/
ml, Molecular Probes, B13423) in FBS-supplemented DMEM 20% for
50min at 37 °C. Muscle were extensively washed with FBS-supple-
mented DMEM 20%, then with PBS. Twenty-micrometer serial long-
itudinal cryosections were collected on poly-lysine coated objective
slides (VWR International, Radnor USA) for the quantitative evaluation
of NMJ status. Images were digitized using a CoolSNAP camera
(Photometrics) coupled to an ECLIPSE Ti-S microscope (Nikon) and
processed using MetaMorph 7.6.5.0 image analysis software (Molecular
Device). Images of acetylcholine receptors (AChRs) immuno-stained
with α-BTX were used for the quantification of NMJ fragmentation.
Fragmentation of NMJ was defined as several AChR clusters in small
islands with round shape. Average numbers of AChR fragments per
NMJ were evaluated. For the quantitative evaluation, about 130 NMJs
for each group were analyzed.
2.14. Cell-attached recordings and analysis
Single-channel currents were recorded at room temperature
(24–26 °C) in the cell-attached mode from dissociated muscle fibres
from hSOD1G93A or non-tg mice and bathed in dissociation medium
without divalent ions to prevent contractions. Glass pipettes (3–5MΩ)
pulled with a vertical puller (PC-10, Narishige) were filled with diva-
lent-free NES (NaCl 140mM, KCl 2.8mM, Glucose 10mM, HEPES/
NaOH 10mM, pH 7.3, 295–300mOsm) plus ACh 200 nM and were
connected to a low-noise amplifier (Multiclamp 700B amplifier,
Molecular Devices, USA). Data were sampled at 20 kHz and analysed
after Gaussian digital filtering at 6 kHz, using a threshold-crossing
method (pClamp v. 10.0 software, Axon Instruments), with the detec-
tion threshold for channel events set to half-amplitude. Events briefer
than 120 μs were incompletely resolved and therefore excluded from
the analysis. The histogram of channel amplitudes was adequately
fitted by one or two Gaussian distributions and slope conductances
were calculated by least-squares linear fitting of unitary current (i)/
voltage (V) relationships. Only single openings were used to calculate
the mean channel amplitude and the apparent open duration (τop),
which was measured at half-amplitude for each event. The kinetic
properties of ACh-evoked events were compared at an estimated patch
potential of−90 ± 10mV. Only patch with at least 1000 events were
used to perform open channel duration analysis. Results are given as
mean ± SEM. The significance of differences was tested by using one-
way ANOVA (P < 0.05) and Fisher’s test.
2.15. Statistical analysis
Data are expressed as the mean ± S.E.M. Student's t-test, paired t-
test, Fisher’s test, one-way or two-way analysis of variance (ANOVA)
was performed. A value of P < 0.05 was considered significant. All
statistical analyses were carried out using the Sigma Plot 11.0 Software
(Systat Software GmbH, Erkrath, Germany). Mouse survival was ana-
lyzed with the Kaplan–Meier graph followed by log-rank statistics. The
sample size (n) was chosen differently for experiments of animal sur-
vival, behavioural tests, electrophysiology, etc, considering the fol-
lowing relation: n≥ 2σ2 (zα/D)2 where sigma is substituted by an es-
timate of variance (s2); alpha is at 0.05 (and Zα=−2) and D is the
difference among treatments.
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3. Results
3.1. KCa3.1 channels modulate spinal microglia in hSOD1G93A mice
In the CNS, KCa3.1 is highly expressed in activated microglia
(Kaushal et al., 2007). To investigate the possible involvement of
KCa3.1 channels in modulating the phenotype of microglia in the fully
symptomatic phase of ALS, we first analyzed the mRNA level of kcnn4,
by quantitative real time PCR (qRT-PCR), in microglia isolated from the
lumbar region of the spinal cord of 18 week-old hSOD1G93A mice.
Preliminarily, we confirmed that these cells have increased expression
of selected inflammatory genes and reduced expression of anti-in-
flammatory ones (Fig. 1A, left), as previously described in ALS mice
(Liao et al., 2012; Apolloni et al., 2016). We found that hSOD1G93A
microglia express high level of kcnn4 (7.54 fold increase in comparison
with age-matched non-tg wt mice), suggesting that KCa3.1 channels
could play a role in the pro-inflammatory microenvironment observed
in ALS (Fig. 1A, right). To directly evaluate the role of KCa3.1 channel
activity in modulating microglia phenotype, hSOD1G93A mice were
treated with TRAM-34 (daily, 120mg/kg) from 7weeks of age (pre-
symptomatic stage) until 18 weeks (fully symptomatic stage) (Fig. 1B,
top). The long term treatment is not toxic and does not induce changes
in body weight, haematology, blood chemistry or necropsy of any major
organs, either in mice or rats (Toyama et al., 2008; Chen et al., 2011).
After this period, microglial cells were isolated and analyzed as in A. As
shown in Fig. 1B, pharmacological KCa3.1 inhibition changed the ex-
pression level of several inflammatory genes in hSOD1G93A microglia
(left), decreasing inos, tnf-α, il-1β, il-6 and p2yr6 expression compared to
microglia obtained from vehicle-treated hSOD1G93A mice (dotted line).
Interestingly, treatment with TRAM-34 also reduced kcnn4 expression
(to 0.27 ± 0.09 fold) compared to vehicle-treated mice. In contrast,
KCa3.1 inhibition increased the expression of the anti-inflammatory
genes arg1, cd163, sosc3, ym1, bdnf and p2yr12 (Fig. 1B, right). As a
control, we also analyzed gene expression in microglia isolated from the
lumbar spinal cord of non-tg wt mice, upon vehicle and TRAM-34 (four
weeks) treatment. Results obtained indicate that KCa3.1 inhibition in-
duces significant increases of arg1 and ym1 genes (see Supplementary
Table 2).
Immunofluorescence analysis of the spinal cord, revealed that
KCa3.1 inhibition, in hSOD1G93A mice (scheme of mice treatment in
Fig. 1. KCa3.1 channels shape microglia activation in ALS. A: Relative ex-
pression level of inos, tnf-α, il-1β, cd163 and arg1 (left) and kcnn4 (right) in
microglial cells isolated from 18week-old hSOD1G93A mice compared to each
gene in wtmice (dotted line) (data are shown as mean ± SEM, n= 3, *< 0.05,
*** p < 0.001 vs wt, Student's t test). B: top, treatment scheme. RT-PCR ana-
lyses of the relative expression level of pro- (left) and anti- (right) inflammatory
and kcnn4 genes in microglia cells isolated from the lumbar region of the spinal
cord of hSOD1G93A mice expressed as fold increase of TRAM-34-treated vs ve-
hicle treated mice (dotted line); data are shown as mean fold increase ± SEM;
*p < 0.05, ** p < 0.01, *** p < 0.001 vs vehicle by Student's t-test n= 6, C:
top, treatment scheme. Quantification of Iba1+ (upper panel) and GFAP+
(lower panel) staining in the lumbar region of the spinal cord of vehicle (white
bar) and TRAM-34 treated (black bar) mice (data are shown as mean ± SEM.
*** p < 0.001 vs vehicle by Student's t test, n= 5 vehicle, n= 6 TRAM-34).
Representative immunofluorescence images are shown on the right (scale
bar= 20 μm). D: Morphological analysis of lumbar Iba1+ cells: from left, soma
area (TRAM-34 50.92 ± 10.36 μm2 vs vehicle 74.23 ± 9.59 μm2
*p < 0.002), scanning domain (TRAM-34 1221.75 ± 113.68 μm vs vehicle
683.20 ± 35.27 μm *p < 0.010), number of branches per cell (TRAM-34
167.88 ± 21.56 vs vehicle 100.50 ± 37.19 ***p < 0.001), junctions (total,
85.56 ± 10.67 vs 52.03 ± 18.80; triple, 64.71 ± 7.34 vs 41.62 ± 13.66;
quadruple 14.02 ± 2.24 vs 7.29 ± 3.63 ***p < 0.001) (data are shown as
mean ± SEM, 20 cells, 6 slices, 4 mice per condition, by Student’s t-test).
Bottom: representative images of maximum intensity projections of a confocal
z-stack imaging of Iba1+ cells, converted to binary images and then skeleto-
nized (scale bar= 20 μm).
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Fig. 1C, top), significantly decreased Iba1 and GFAP staining in the L3-
L5 regions, compared to vehicle-treated mice (Fig. 1C, center and
bottom), further confirming the induction of a reduced inflammatory
environment. Iba1-positive cells in these spinal sections were also
analyzed for morphological changes by performing skeleton analysis to
quantify single cell shape. The data summarized in Fig. 1D, reveal that
Iba-1 positive cells from TRAM-34 treated mice had significantly
smaller somas, bigger scanning domains and higher average branch
numbers. Skeleton analysis also evidenced higher number of junctions
and more triple as well as quadruple junction points, when compared to
vehicle-treated animals. Taken together, these results indicate that
KCa3.1 inhibition shifts spinal microglia of hSOD1G93A mice towards an
anti-inflammatory phenotype and increases the active surveillance that
microglia exert in their competence domains. These data consistently
support our hypothesis of KCa3.1 involvement in microglia modulation
in ALS and further prompted us to verify if channel inhibition could
significantly impact disease progression.
3.2. Inhibition of KCa3.1 has beneficial effects in hSOD1G93A mice
To assess the possible beneficial effects of KCa3.1 inhibition on ALS
progression, we treated hSOD1G93A mice daily with TRAM-34 or vehicle
(as detailed above) from 7-weeks of age until sacrifice (Fig. 2A). Mice
were evaluated during the treatment period for changes in weight, lo-
comotor activity, muscle strength, motor coordination and survival. As
shown in Fig. 2B, TRAM-34 treatment significantly increased body
weight from week 13 to the end stage. Disease onset was retrospectively
determined as the age when these mice reached their maximal body
weight: KCa3.1 inhibition delayed disease onset of about 3 weeks in
hSOD1G93A mice (Fig. 2C). In addition, KCa3.1 inhibition increased
survival time (Fig. 2D) compared to vehicle treated mice and sig-
nificantly prolonged the mean survival time post-paralysis, assessed as
the age when mice failed to complete the Rotarod test (Fig. 2E).
We also tested locomotor ability, muscle strength and motor co-
ordination in vehicle and TRAM-34 treated hSOD1G93A mice. The re-
sults of these experiments show that in the hanging wire test, the
TRAM-34 treated mice (Fig. 2F and G), for the time investigated, always
performed with higher scores and spent more time hanging compared
to controls. Of note, the TRAM-34-treated mice never reached the
lowest score (1) during the symptomatic stage (13–18weeks), showing
a very good, preserved, locomotor ability. In the inverted grid test
(Fig. 2H), the average latency to fall recorded for TRAM-34-treated
Fig. 2. KCa3.1 channels modulate motor function and survival in hSOD1G93A mice. A: Treatment scheme. B: Variations of body weight over time in vehicle (white)
and TRAM-34-treated hSOD1G93A mice (black dots). Data are the mean ± SEM; *p < 0.05, ** p < 0.01, *** p < 0.001 vs vehicle by Student's t-test n=9. C:
Disease onset index, calculated as the age of peak of body weight. Disease onset in TRAM-34 treated mice was 19.3 ± 0.2 weeks, black bars; in vehicle
16.3 ± 0.2 weeks, white bars. Data are the mean ± SEM *** p < 0.001, n= 9. D: Kaplan–Meier analysis of mice survival. TRAM-34 increased the survival time of
hSOD1G93A mice (TRAM-34: 165 ± 2 days; vehicle: 148 ± 7 days, data are the mean ± SEM *p < 0.008 by Log–rank test, n= 9). E: Quantification of the mean
survival time post-paralysis. TRAM-34: 16.6 ± 2.41 days (black bar); vehicle: 7.4 ± 0.97 days (white bar) data are the mean ± SEM, n= 9 ***p < 0.001 by
Student's t test. F-M: Analyses of motor function in SOD1G93A mice treated with TRAM-34 (black dots) or vehicle (white dots) with: hanging wire test, score (F) and
latency (G), inverted grid test (H), rotarod test (I), grip strength test (force) (L) and extension reflex (M). Behavioral tests were performed once a week, starting from
7-weeks of age until weeks described in the panels. All behavioral tests were ameliorated by TRAM-34 treatment. Data are expressed as mean ± SEM; *p < 0.05, **
p < 0.01, *** p < 0.001 vs vehicle hSOD1G93A mice by Student's t-test n= 9.
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mice was longer compared to vehicle-treated mice at all the time point
analyzed. hSOD1G93A mice were further tested for motor coordination
and balance using a Rotarod apparatus. Mice treated with TRAM-34
performed better on the Rotarod (Fig. 2I) and continued to do so until
week-21. The grip strength data (Fig. 2L) obtained for TRAM-34 treated
mice showed that the rate of muscle deterioration was lower compared
to vehicle treated mice, suggesting a slower disease progression. In
addition, mice treated with TRAM-34 showed a preserved hind-limb
extension reflex (Fig. 2M) compared to vehicle treated mice from the
beginning of the symptomatic stage. Taken together, these results show
that KCa3.1 inhibition significantly delays symptom onset, suggesting
that these channels are involved in accelerating disease progression.
3.3. Motor neurons are protected by selective KCa3.1 inhibition in
hSOD1G93Amice
In order to investigate if the activity of KCa3.1 channels in microglia
could be involved in MN death in ALS, another group of hSOD1G93A
mice were treated with TRAM-34 or vehicle from the pre-symptomatic
until the disease onset phase (from 7weeks to 16 weeks of age, scheme
on top of Fig. 3A) when the spinal cords were collected. MNs in the
ventral horns of the spinal cord regions L3-L5 were stained with an
antibody against the non-phosphorylated neurofilament H (SMI32) (a
MN marker) and cells with large cell body (diameter≥ 20 µm) were
counted. The mean number of MNs in wt animals was taken as control
value. As shown in Fig. 3A, KCa3.1 inhibition, in hSOD1G93A mice,
increased MN survival (TRAM-34 52.00 ± 3.13%, vehicle
38.26 ± 1.38% vs wt 100 ± 1.09%). Taking advantage of a microglia/
MN co-culture system, we then evaluated the specific communication
between MN and microglial cells. To this aim, primary adult microglia
isolated from symptomatic (16weeks) or end-stage (> 20weeks)
hSOD1G93A mice were co-cultured with MNs isolated from the spinal
cord of mouse embryos (E13) and treated with 2.5 µM TRAM-34 or
vehicle (DMSO). After 72 h of co-culture, MN death was measured by
staining with SMI32 and the activated caspase 3 antibody, as an
apoptosis marker. As shown in Fig. 3B, co-cultures with both sympto-
matic and end-stage hSOD1G93A microglia induced MN death (apoptotic
MNs in symptomatic and end-stage were respectively, 83.3 ± 2.5%
and 78.1 ± 1.6%), while co-culture with wt microglia did not (apop-
totic MNs were 17.8 ± 1.7%), in accordance with (Frakes et al., 2014).
In the presence of the KCa3.1 inhibitor, MN death induced by
hSOD1G93A microglia was prevented or significantly decreased (symp-
tomatic microglia: 12.1 ± 1.4%; end-stage: 28 ± 1.5%; wt:
17.8 ± 1.7%). These data indicate that KCa3.1 channel activity on
microglia influences microglia-MN communication, increasing MN
death in hSOD1G93A mice.
Fig. 3. KCa3.1 channels modulate microglia-motor neuron interaction in hSOD1G93A mice. A: top, treatment scheme. Bottom, quantification of MNs (counted as SMI-
32 stained cells in the ventral horns of the spinal cord) in non-tg wt, and hSOD1G93A mice treated with vehicle or TRAM-34. Data are shown as mean ± SEM
***p < 0.001 vs wt; ###p < 0.001 vs vehicle by One Way ANOVA, TRAM-34n=6; Vehicle n= 5; wt n=3). Representative immunofluorescence images are
shown on the right (scale bar= 20 μm). B Non-tg wt MNs co-cultured with microglia isolated from the spinal cord of wt, symptomatic or end-stage hSOD1G93A mice
treated with TRAM-34 (2.5 μM, black bars) or DMSO (white bars). After 72 h, MN death was quantified counting the activated caspase 3/SMI32 double positive cells.
Data are mean ± SEM; n= 3 in triplicate, °°°p < 0.001 vs wt microglia, ***p < 0.001 vs symptomatic microglia, ###p < 0.001 vs end-stage microglia, @@@
p < 0.001 vs wt microglia+ TRAM-34 by Two Way ANOVA (Holm-Sidak method): Representative immunofluorescence images are shown on the right (scale
bar= 20 μm).
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3.4. Selective KCa3.1 inhibition counteracts ROS-induced microglia
neurotoxicity
Mitochondrial reactive oxygen species (ROS) play a prominent role
in the oxidative stress observed in ALS (Barber et al., 2010). To in-
vestigate whether KCa3.1 activity modulates ROS production in mi-
croglia, we used sodium azide (NaN3), an inhibitor of the electron
transport chain, to increase ROS levels (Ye et al., 2016). Microglia
(from wt mice) were therefore treated with 5 µM NaN3 for 18 h, in the
presence or absence of TRAM-34 (2.5 µM) or vehicle, and mitochon-
drial ROS production was evaluated by loading cells with 10 µM 2′,7′-
dichlorofluorescin diacetate (DCF). Alternatively, microglia were co-
incubated for additional 24 h with primary MN to evaluate neurotoxi-
city.
The data reported in Fig. 4A show that NaN3 treatment induced ROS
production in microglia and that KCa3.1 channel inhibition reduced it,
as measured by cytofluorimetric analysis (DCF+ microglial cells were:
NaN3: 5.4 ± 0.3%; NaN3+TRAM-34: 2.8 ± 0.4%). In accordance,
MN death (measured as above) increased when MNs were co-cultured
for 48 h with microglia pre-treated with NaN3 (Fig. 4B, 19.06 ± 0.8%
control microglia; 71.6 ± 2.04% NaN3 microglia). Neurotoxicity was
abolished when MNs were co-cultured with microglia pre-treated with
NaN3/TRAM-34 (22.06 ± 1.98%), suggesting that KCa3.1 function is
involved in sustaining ROS production in microglia. As shown in the
first two bars of Fig. 4B, TRAM-34 exerted a minor neuroprotective
action also in control co-cultures.
3.5. Selective KCa3.1 inhibition preserves neuromuscular junction (NMJ)
functionality
In hSOD1G93A mice, muscle force and motor coordination start to
decline at about 10–11weeks, with clear evidence of NMJ alterations
(Dobrowolny et al., 2011). The functional data reported above suggest
that NMJ is preserved for longer time in animals treated with TRAM-34.
Therefore, we performed morphological and functional analysis of NMJ
in hSOD1G93A mice treated with TRAM-34 or vehicle from 7-to 16-
weeks of age (Fig. 5A, left). To evaluate the NMJ morphology/integrity,
the tibialis anterior (TA) muscle was isolated, stretched and fixed.
Bundles of muscle fibres were stained with alpha-bungarotoxin (α-BTX)
and analyzed for NMJ fragmentation. In symptomatic, vehicle treated
mice, the average acetylcholine receptor (AChR)-rich fragments per
NMJ were 2.07 ± 0.18 (vehicle n=3, 136 NMJs) and in TRAM-34-
treated hSOD1G93A mice this value drops to 0.96 ± 0.06 (TRAM-
34n=4, 135 NMJs), not dissimilar to what was observed in non-tg age
matched mice (0.4 ± 0.06 per NMJ, non-tg n= 3, 148 NMJs) (see
Fig. 5A, center and right for representative images).
Several signaling pathways contribute to skeletal muscle atrophy in
ALS patients as well as in hSOD1G93A mice (Krasnianski et al., 2005;
Dupuis et al., 2006). Increased expression of the late myogenic tran-
scription factor myogenin (myf4) and the muscle-specific E3 ubiquitin
ligase (atrogin 1) were detected in both mouse (Manzano et al., 2011)
and human ALS muscles (Léger et al., 2006). As shown in Fig. 5B, the
mRNA level of atrogin1 and myogenin were reduced in TRAM-34- vs
vehicle-treated hSOD1G93A mice (respectively 0.27-fold and 0.69-fold;
vehicle n= 3 TRAM-34n=4 atro gin *p < 0.002 vs vehicle, myogenin
***p < 0.001 vs vehicle).
We also measured the expression level of AchRγ and ε subunits in
vehicle and TRAM-34 treated mice, an index for NMJ denervation
(Martinou and Merlie, 1991). In hSOD1G93A muscle, at the paralysis
stage, expression of AChRγ was upregulated, in agreement with pre-
vious studies (Krasnianski et al., 2005). Data reported in Fig. 5C show a
decreased (0.59-fold) AChR γ and an increased (3.08-fold) AChR ε ex-
pression in TRAM-34 treated hSOD1G93A mice (vehicle n= 4 TRAM-
34n=6, AChRγ ***p < 0.001 vs vehicle, AChRε ***p < 0.001 vs
vehicle).
To assess whether TRAM-34 treatment preserves AChR function-
ality, patch-clamp recordings were performed in acutely dissociated
flexor digitorum brevis (FDB) muscle fibres. The single channel proper-
ties of AChRs were investigated under cell-attached conditions at the
end-plate region. To improve the mechanical stability of the patches,
recordings were performed with pipette solutions free of Ca2+ and
Mg2+ ions. In all recordings obtained from wt mice (13 fibres/5 ani-
mals) only one population of ACh-activated channels was observed
(Fig. 5D, left). Unitary channel slope conductance was
78.23 ± 1.71 pS, as expected for AChRε in the absence of divalent
cations. By contrast, in 7 out of 11 recordings obtained in end-plates
from 16-weeks old, vehicle treated SOD1G93A mice (5 mice) two po-
pulation of channels, differing in amplitude, were observed (Fig. 5D,
middle). Slope conductances were 53.15 ± 1.96 pS (23%) and
82.56 ± 1.28 pS (77%), typical values for γ- and ε- containing AChRs,
respectively. As expected, based on the data reported above, only one
population of ACh-evoked channel openings was detected in 10 out of
12 recordings (6 mice) in TRAM-34 treated hSOD1G93A mice (Fig. 5D,
right). Channel slope conductance was 79.22 ± 1.75 pS. In 2 fibres, a
Fig. 4. MNs are protected against ROS neurotoxicity by TRAM-34 treated microglia. A: Quantification of ROS production in non-tg wt microglia treated with NaN3
(5 μM), vehicle (DMSO, control) or TRAM-34 (2.5 μM) for 18 h, measured as dichlorofluorescein positive cells by cytofluorimetry (Data are expressed as % of DCF+
microglia, mean ± SEM, n= 3 in triplicate, **p= 0.005 vs C; #p=0.048, ##p=0.004 vs NaN3 by Two Way ANOVA (Holm-Sidak method). B: Cell death
quantification of MNs co-cultured for 24 h with non-tg wt microglia pre-treated as in A. Data are expressed as % of active-caspase 3/SMI32 double positive cells on
SMI32 positive cells in each condition and are the mean ± SEM. n=3 in triplicate, ***p < 0.001, *p= 0.037 vs control, ## p=0.003, ### p < 0.001 vs NaN3,
°°p= 0.003 vs TRAM-34 by Two Way ANOVA (Holm-Sidak method). Representative immunofluorescence images are shown on the right (scale bar= 20 μm).
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small fraction of openings belonged to a population with 38.1 and
59.34 pS slope conductance. Thus, the number of fibres expressing
AChRγ channel was significantly reduced in TRAM-34-treated
hSOD1G93A mice (p= 0.0009, Fisher's exact test). The slope con-
ductance of AChRε showed no statistically significant difference among
groups. The histograms of AChRε channel open duration were fitted to
the sum of three exponential components which did not differ among
the groups (Suppl. Table 1) showing that the function of AChR channels
is not perturbed in hSOD1G93A mice.
4. Discussion
Increasing evidence supports the hypothesis that in ALS, a neu-
roinflammatory microenvironment support MN degeneration (Fiala
et al., 2010; Puentes et al., 2016; Pasetto et al., 2017; Vallarola et al.,
2018). In this paper we demonstrated that in hSOD1G93A, a mouse
model of fALS, spinal microglia overexpress the calcium-activated po-
tassium channel, KCa3.1, and that blockade of this channel induces a
significant delay in the appearance of all symptoms, preserving motor
function and slowing disease progression. In the CNS, KCa3.1 is ex-
pressed by microglia and transformed cells (Kaushal et al., 2007;
Manzano et al., 2011) and, in a model of spinal cord injury, it has been
detected on neurons and astrocytes (Bouhy et al., 2011). In our ex-
perimental conditions, we never measured KCa3.1 activity or expres-
sion in spinal MN of wt and hSOD1G93A mice. KCa3.1 channels ex-
pressed on microglial cell play important roles in neurodegenerative
diseases and in brain tumors modulating cell phenotype (D’Alessandro
et al., 2018; Nguyen et al., 2017). The expression of the mutant
SOD1G93A gene in microglia has been related to MN degeneration and
to ALS progression (Boillée et al., 2006; Beers et al., 2006). Here we
tested the hypothesis that the activity of KCa3.1 channels is associated
to a pro-inflammatory phenotype of microglial cells, that favors MN
death and disease progression. This is the first study that investigate the
role of KCa3.1 channels in ALS, and we demonstrated that the chronic
treatment of hSOD1G93A mice with the KCa3.1 channel inhibitor TRAM-
34 modulates the phenotype of spinal microglia. In both ALS patients
and mouse models, the expression of pro-inflammatory genes increases
(Lu et al., 2016; Lee et al., 2016), while anti-inflammatory genes de-
crease (Liao et al., 2012; Apolloni et al., 2016; Lewis et al., 2014). In
line with our hypothesis, we observed that TRAM-34 treatment reverts
this trend, increasing the anti-inflammatory (such as arg1, cd163, socs3,
and ym1) and decreasing several pro-inflammatory genes (il1β, tnf-α, il6
and inos) in spinal microglia of hSOD1G93A mice. Interestingly, KCa3.1
blockade induces some phenotypic changes also in microglia of wtmice,
increasing the expression of arg1 and ym1 genes, further confirming the
role of this channel in the modulation of microglia phenotype. Like in
other neurodegenerative diseases and similarly to brain tumors, mi-
croglia play a dual role in early and late stages of ALS (Ferreira and
Bernardino, 2015). A recent data-driven experimental approach re-
vealed a link between microglia and the development of MN pathology,
identifying soluble TREM2 in the CSF as a putative marker of disease
progression (Cooper-Knock et al., 2017).
Fig. 5. KCa3.1 channel inhibition ameliorates NMJs functionality. A: left, treatment scheme. Center, AChR fragments per NMJ in the different conditions, as
indicated (mean ± SEM, n= 4 mice; *p < 0.05, ***p < 0.001 vs wt, ###p < 0.001 vs vehicle; 130 α-BTX-positive NMJ per group were randomly chosen and
analyzed). Right, representative images of tibialis anterior (TA) muscles stained with α-BTX for each experimental group (scale bar= 20 μm). B: Relative expression of
atg1 and myf4 in the TA muscle of 16-weeks old mice. Data are normalized to GAPDH and expressed as fold changes ± SEM vs vehicle treated hSOD1G93A mice
(n=3–4). C: Relative expression of γ and ε AChR in TA muscles from vehicle and TRAM-34-treated hSOD1G93A mice. Data are normalized to GAPDH and expressed
as fold changes ± SEM vs vehicle. D: Single channel recordings of (ACh)-evoked unitary events in FDB muscle fibres dissociated from non-tg, vehicle and TRAM-34
treated hSOD1G93A mice. In the top and middle, non-consecutive traces recorded in an end-plate evoked by ACh (200 μM) at an estimated patch potential of−85mV.
Dotted lines indicate openings of ACh-γ found only in vehicle hSOD1G93A mice. Lower, histograms of the of unitary events, best fitted by two Gaussian functions
(continuous line) only in the vehicle hSOD1G93A group.
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Expression of other genes, potentially relevant to microglia function
and MN death, is also altered by blockade of KCa3.1 channels, in
agreement with the induction of an anti-inflammatory phenotype. For
example, the expression of the p2yr6 gene is increased in spinal
hSOD1G93A microglia (D'Ambrosi et al., 2009), and we observed that
TRAM-34 treatment prevents this overexpression. P2Y6 purinergic re-
ceptors are involved in microglia phagocytosis (Koizumi et al., 2007;
Brown and Neher, 2014) and related to MN loss in ALS (D'Ambrosi
et al., 2009). The phagocytic activity of microglia has debated roles in
ALS, where it controls the removal of MNs at different stages of the
disease (D'Ambrosi et al., 2009; Butovsky et al., 2014). Interestingly,
recent data (Paolicelli et al., 2017), demonstrate that TDP-43, a gene
associated with ALS, controls microglia phagocytic activity.
The expression of BDNF, insulin-like growth factor-1 (IGF-1), fi-
broblast growth factor-2 (FGF-2), and vascular endothelial growth
factor are all downregulated in ALS patients (Shruthi et al., 2017;
Ohsawa et al., 2010). We observed that the expression of the neuro-
protective factor bdnf is boosted in hSOD1G93A microglia by inhibiting
KCa3.1 activity.
In line with the gene expression data, spinal microglia of TRAM-34
treated hSOD1G93A mice at symptomatic stage are less amoeboid, have
smaller soma and higher branching complexity. These morphology data
reveal that blockade of KCa3.1 activity restores the patrolling activity of
microglia in hSOD1G93A mice. This is in accordance with the higher
expression of the metabotropic receptor P2Y12, known to be involved
in microglia process mobility (Appel et al., 2011).
Microglia-MN communication in hSOD1G93A mice also benefits from
the blockade of KCa3.1 channels. The observed neuroprotective effect is
likely due to the combination of a reduced inflammatory phenotype and
an increased production of the neurotrophin BDNF. Taken together,
these data confirm a key role for KCa3.1 in mediating a pro-in-
flammatory microglia behavior, as described in other CNS diseases,
such as AD, multiple sclerosis, spinal cord injury and ischemia
(Maezawa et al., 2011; Moloney et al., 2014; Kaushal et al., 2007; Chen
et al., 2016).
These findings are associated with a reduced NMJ damage, seen as
less fragmented and better-preserved structure, together with a de-
creased muscle denervation, demonstrated by a shift in the expression
of the γ and ε AChR subunits in hSOD1G93A mice treated with TRAM-34.
We interpret the enhanced expression of the ε AChR subunit as a con-
sequence of ongoing denervation/reinnervation cycles in TRAM-34
treated mice. Functional recordings on FDB fibres confirmed the ex-
pression data. In addition, KCa3.1 inhibition induced a decrease in the
expression markers of atrophy normally detected in ALS muscle
(Dobrowolny et al., 2011), such as myogenin and the E3 ubiquitin li-
gase atrogin 1.
Degeneration of NMJs together with multiple pathogenic mechan-
isms such as oxidative stress, aberrant protein aggregation, defective
axonal transport, neuroinflammation and mitochondrial dysfunction,
all contribute to MN failure in ALS (Philips and Robberecht, 2011;
Barber and Shaw, 2010; Blokhuis et al., 2013; Barber et al., 2006). In
particular, mitochondrial ROS play a prominent role in the oxidative
stress observed in ALS (Barber and Shaw, 2010). We used low con-
centrations of sodium azide to block the electron transport chain and to
induce effects on microglia neurotoxic properties (see Ye et al., 2016),
and observed that KCa3.1 inhibition prevented the consequent increase
in ROS production in microglial cells. Notably, in addition to the
plasma membrane, KCa3.1 (and other Ca2+ activated potassium
channels such as KCa1.1) are also expressed in the inner membrane of
the mitochondria in transformed cells and cardiomyocytes (De Marchi
et al., 2009; Aldakkak et al., 2010). KCa1.1 activation increases re-
spiration and ROS generation in cardiac cells providing protection
against ischemia and reperfusion (IR) injury (Stowe et al., 2006). We
hypothesize that, at least the effect of KCa3.1 inhibition on ROS pro-
duction, could be partially due to the perturbation of K+ homeostasis
between the mitochondrial matrix and the inter membrane space.
It has been shown that, in GBM, histamine activates KCa3.1 chan-
nels through cell hyperpolarization, which in turn induces Ca2+ influx
(Fioretti et al., 2009); clemastine, a histamine receptor (H1R) antago-
nist, ameliorates ALS pathology modulating inflammatory parameters
(Apolloni et al., 2016). Our results are in accordance with a possible
mechanism where histamine, released by peripheral mast cells, acti-
vates KCa3.1; blocking H1R would also reduce KCa3.1 activity, thus
affecting ALS progression.
4.1. Conclusions
In conclusion, our data indicate that the blockade of KCa3.1, when
initiated in the pre- symptomatic stage of the disease, elicits broad
protective effects in hSOD1G93A mice inducing: i) anti-inflammatory
phenotype in microglia, that re-acquire a proper scanning domain; ii)
reduced MN degeneration; iii) an overall delay of disease onset and
motor dysfunction and iv) increased mean survival time. Overall, these
data describe, for the first time, a critical role for KCa3.1 activity in
modulating ALS onset and progression, at least in the hSOD1G93A
murine model investigated here. It remains to be clarified: i) whether
the effect of the blockade of KCa3.1 on hSOD1G93A mice could be re-
levant in other familiar forms of ALS, and in sALS; ii) the involvement
of other target cells such as immune cells or other parenchymal cells. As
a potential future application, it is worth to mention that a molecule
structurally related to TRAM-34, Senicapoc®, which advanced into
Phase-3 clinical trials, has been proven safe in humans (Ataga et al.,
2011). Our data demonstrate that KCa3.1 is a potential target to
counteract neuroinflammation and neuromuscular degeneration, at
least in familial ALS.
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CONCLUSIONS AND PERSPECTIVES 
 
In this paper we report for the first time that spinal microglia overexpress the calcium-
activated potassium channel, KCa3.1, in hSOD1G93A mice, a model of familial ALS; it is 
well known that this channel is involved in several physiological and pathological cellular 
functions121. We found that the chronic inhibition of KCa3.1 activity in hSOD1G93A mice: i) 
attenuates the pro-inflammatory phenotype of microglia; ii) increases the number of healthy 
MNs; iii) preserves the number of healthy neuromuscular junctions (NMJ) in the tibialis 
anterior muscle; iv) and their maturation level, as assessed by mRNA analysis of AChR γ 
and ε subunit expression and by current recording on isolated muscle fibers. Furthermore, 
TRAM-34 treatment delays motor symptoms appearance, as shown by prolonged muscle 
strength and motor coordination, and increases mice survival. In this work, we focused on 
the effect of KCa3.1 blockade in one mouse model of ALS. However, SOD1 transgenic 
mice are extensively used as preclinical models to test therapeutic strategies. The 
pathological alterations found in SOD1 mice are correlated with features in patient tissues 
and important information on ALS pathology derived from studies on this model. 
Unfortunately, many of the therapeutic strategies, based on single study observations in 
rodent mutant SOD1 models, failed in a mostly sporadic ALS population153. To our 
advantage it is important to stress that, the blockade of KCa3.1, in several pathological 
conditions141,143, has been shown able to counteract cerebral damage associated with 
pathologies leading to a reduction of the microglia neurotoxic potential. In AD, microglial 
KCa3.1 potentiates the neurotoxicity induced by oligomeric amyloid-β and 
lipopolysaccharide (LPS) treatment140,141, while blocking KCa3.1 activity has beneficial 
effects in rodent models of multiple sclerosis and ischemic stroke, reducing TNF-α and IFN-
γ expression in the spinal cord150 or the infarcted area125. The KCa3.1 inhibitor per se is not 
directly neuroprotective in the absence of microglia, indicating a good microglia specificity, 
and has no toxic effects in rodents123,125. These important findings raise the awareness that 
these peculiar channels could be considered as optimal targets for the development of drugs 
against brain diseases, acting on microglia activation state. To corroborate and generalize 
our pre-clinical findings, we plan to use others familial models of ALS to evaluate the role 
of KCa3.1 in the inflammatory response. Among the possible modulators of the 
inflammatory response in the CNS, plasma membrane ion channels are good candidates, 
regulating membrane potential and intracellular signaling also in T cells, B cells and innate 
immune cells such as macrophages 154,155. It would be interesting to investigate the 
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involvement of KCa3.1 activity in inflammatory response also in these cells in the context of 
ALS. Another important aspect that we plan to re-consider in the future work is the disease 
time-window in which to study the effect of KCa3.1 activity on inflammatory response. We 
plan to inhibit channel activity not only before the onset of symptoms, but also later 
considering that the majority ALS patients in clinical trials always surpassed the onset of 
disease. In this case, positive results will be more relevant for the clinical setting, even 
though treatment during the presymptomatic phase already gave us important information 
concerning the preventive effects of KCa3.1 inhibition in a mouse model of ALS. KCa3.1 
inhibition induces a moderate extension on lifespan, likely due to the multi-systemic nature 
of ALS disease in which neuronal and metabolic impairments have been detected and 
multiple cell types are involved. Nevertheless, the robust effect of  KCa3.1 inhibition on 
neuroinflammation warrants further investigation on its value as add-on therapy in ALS. In 
fact, a TRAM-34 analogue (Senicapoc®) already used in clinical trials on patients with 
sickle cell disease (SCD), is safe152, and it is now property of a Pfizer spin out. Our data, 
could suggest to test KCa3.1 inhibitor in a combined treatment, for instance, with 
Riluzole156,157, as a reinforced therapeutic strategy for human trials in ALS. In conclusion, 
our published data demonstrating that KCa3.1 is a good molecular target to reduce ALS-
associated neuroinflammation and to protect MN from degeneration and future research 
perspectives will pave the road to design proof of concept experiments with high 
translational in the context of this fatal disease. 
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